centhaquine

Centhaquine is a novel, first-in-class resuscitative agent developed for the treatment of hypovolemic shock. It acts primarily as an agonist at α2B adrenergic receptors on veins to induce venous constriction and increase venous return to the heart, thereby boosting cardiac output and improving tissue perfusion. Additionally, it stimulates central α2A adrenergic receptors to reduce sympathetic drive and decrease systemic vascular resistance, further enhancing tissue blood flow. Unlike many other agents used in shock management, centhaquine does not act on beta-adrenergic receptors, reducing the risk of arrhythmias. Clinical studies have shown that centhaquine improves blood pressure, lactate levels, base deficit scores, acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS) scores and reduces mortality in patients with hypovolemic shock. It was initially synthesized in India in the 1970s but repurposed after its unique hemodynamic effects were discovered at lower doses[1][3][5][6][8].

Brand names

Lyfaquin

Other names

2-[2-[4-(3-Methylphenyl)-1-piperazinyl] ethyl] quinoline citratecenthaquine citrate